内容摘要："I don't want to go there. That's my girl [Tracy] who I made everything happen for," Dame Jacqueline told an audience at the Hay Festival.

"I don't want to go there. That's my girl [Tracy] who I made everything happen for," Dame Jacqueline told an audience at the Hay Festival.

The federal home ministry'snotes a 48% drop in violent incidents in Maoist-related violence - from 1,136 in 2013 to 594 in 2023 - and a 65% decline in related deaths, from 397 to 138.

However, it acknowledges a slight rise in security force casualties in 2023 compared to 2022, attributed to intensified operations in core Maoist areas.The report says Chhattisgarh remained the worst-affected state in 2023, accounting for 63% of all Left-Wing Extremism (LWE) incidents and 66% of the related deaths.Jharkhand followed, with 27% of the violence and 23% of the deaths. The remaining incidents were reported from Maharashtra, Odisha, Madhya Pradesh and Bihar.

The collapse of Maoism in Chhattisgarh, a stronghold of the insurgency, offers key clues to the movement's broader decline.A decade ago, the state's police were seen as weak, according to Mr Ganapathy.

"Today, precise state-led strikes, backed by central paramilitary forces, have changed the game. While paramilitary held the ground, state forces gathered intelligence and launched targeted operations. It was clear role delineation and coordination," he said.

Mr Ganapathy adds that access to mobile phones, social media, roads and connectivity have made people more aware and less inclined to support an armed underground movement."What this drug can do for me is allow me to see my son's wedding next year and to look into the future."

Despite its approval for use globally by the US Food and Drug Administration (FDA) in 2023, capivasertib only became available to patients via the NHS in England and Wales this year.Dr Simon Waters, consultant medical oncologist at Velindre Cancer Centre, said it was a "great opportunity now we've got to this point".

"People have been working on it for a long time. It's great we can now put it in to practice as a standard treatment," he said."We've been using a similar treatment for a smaller group of patients for a few years and that's had quite a lot of issues with side effects and we think this treatment will not only be more effective but also will have fewer issues with side effects.